The US Food and Drug Administration is asking cancer drug sponsors to think about the studies intended to support accelerated approval, as well as those aimed at confirming clinical benefit postapproval, as a single package when bringing their development plans to the agency.
The goal is to have an early, comprehensive discussion with the agency to ensure that appropriate data are generated for accelerated approval and the confirmatory trials are completed in a timely fashion, Oncology Center of Excellence director Richard Pazdur said at a Friends of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?